Kent Hawryluk, MBX Biosciences CEO
MBX seeks $114M IPO to compete with Ascendis and get a long-acting GLP-1/GIP prodrug into the clinic
MBX Biosciences is the latest IPO contender after submitting its pitch for a $114 million Nasdaq debut, which will go toward …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
